- Home
- NTRB vs PSNL Comparison
NTRB vs PSNL Comparison
Compare NTRB & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- PSNL
- Stock Information
- Founded
- NTRB 2016
- PSNL 2011
- Country
- NTRB United States
- PSNL United States
- Employees
- NTRB N/A
- PSNL N/A
- Industry
- NTRB Industrial Specialties
- PSNL Medical Specialities
- Sector
- NTRB Health Care
- PSNL Health Care
- Exchange
- NTRB Nasdaq
- PSNL Nasdaq
- Market Cap
- NTRB 71.8M
- PSNL 518.8M
- IPO Year
- NTRB N/A
- PSNL 2019
- Fundamental
- Price
- NTRB $6.86
- PSNL $5.70
- Analyst Decision
- NTRB Buy
- PSNL Strong Buy
- Analyst Count
- NTRB 1
- PSNL 4
- Target Price
- NTRB $13.00
- PSNL $8.13
- AVG Volume (30 Days)
- NTRB 32.3K
- PSNL 835.5K
- Earning Date
- NTRB 09-09-2025
- PSNL 11-05-2025
- Dividend Yield
- NTRB N/A
- PSNL N/A
- EPS Growth
- NTRB N/A
- PSNL N/A
- EPS
- NTRB N/A
- PSNL N/A
- Revenue
- NTRB $2,578,059.00
- PSNL $80,317,000.00
- Revenue This Year
- NTRB $560.75
- PSNL N/A
- Revenue Next Year
- NTRB $588.39
- PSNL $29.83
- P/E Ratio
- NTRB N/A
- PSNL N/A
- Revenue Growth
- NTRB 42.92
- PSNL 0.36
- 52 Week Low
- NTRB $2.98
- PSNL $2.83
- 52 Week High
- NTRB $9.42
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- NTRB 52.51
- PSNL 59.04
- Support Level
- NTRB $6.69
- PSNL $4.73
- Resistance Level
- NTRB $7.48
- PSNL $6.26
- Average True Range (ATR)
- NTRB 0.46
- PSNL 0.32
- MACD
- NTRB 0.13
- PSNL 0.12
- Stochastic Oscillator
- NTRB 62.92
- PSNL 67.87
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.